It moved two categories of marijuana from Schedule I to Schedule III of the Controlled Substances Act. The first is marijuana contained in an FDA approved drug product. The second is marijuana subject to a qualifying state medical marijuana license.

It also created an expedited federal registration pathway for entities holding those state licenses, and it brought Schedule III marijuana within the federal import and export permit framework.

The order was issued under the Attorney General's treaty implementation authority, which allowed it to take effect on publication without notice and comment rulemaking.

No. A Schedule III substance is a controlled substance. It may be handled lawfully only by a person holding a DEA registration, and only for the activities that registration authorizes.

Adult use marijuana was not rescheduled. It remains in Schedule I, as does unlicensed bulk marijuana and marijuana extract not tied to a covered product.

Marijuana covered by a state medical marijuana license or incorporated into an FDA approved drug product is Schedule III.

A separate administrative proceeding is considering whether marijuana more broadly should move to Schedule III. That proceeding has not concluded.

Synthetically derived tetrahydrocannabinols, including delta 10 THC, remain in Schedule I. The order also does not affect the status of hemp. Separate legislation narrowed the federal definition of hemp so that it turns on total THC concentration rather than delta 9 THC alone, and that change takes effect in November 2026.

Hemp derived THC products sit in a different and unresolved place. The FDA has taken the position that products containing THC cannot lawfully be sold as foods or dietary supplements, and the order did not address that question.

The order provided an expedited review window running sixty days from publication in the Federal Register. The window closed at the end of June 2026.

Applications are still accepted. What a late applicant gives up is the expedited six month review target and the protection that allowed applicants inside the window to keep operating while the DEA reviewed the file.

Yes, and this is the clearest new revenue channel the order created. A DEA registered researcher may now obtain marijuana and marijuana derived products directly from a state licensed operator, provided both parties held valid federal registrations at the time of the transfer.

Before the order, research material had to come through a federally designated source. That monopoly is over. The order further provides that the DEA shall not treat the use of state licensed marijuana products in federally registered research as a basis for adverse action against a researcher's registration.

This opens a business to business channel serving universities, drug developers, and clinical research organizations. Only registrants can enter it. An unregistered operator cannot supply a researcher, and a researcher cannot lawfully accept product from one.

No. Section 280E disallows deductions for businesses trafficking in a Schedule I or Schedule II controlled substance. It is a two part test that gates on schedule status.

Once state licensed medical marijuana moved to Schedule III, the gate closed. The relief follows from the reschedule and attaches to the state license. It does not depend on holding a registration.

You are inside two federal regimes at once. Your medical activity is Schedule III and can be registered. Your adult use activity remains Schedule I and cannot be. The obligation to keep them apart arrived with the reclassification, not with the registration, and it applies whether or not you file.

You have most likely been told to separate operations and recordkeeping. That is the advice circulating in the market, and it may not answer the test that actually applies.

Federal registration law examines the applicant, and the applicant includes its owners. The public interest inquiry asks whether the applicant maintains effective controls against diversion into other than legitimate medical, scientific, and industrial channels. The DEA has denied a registration based on an owner's conduct, rejecting the argument that the owner was not involved in daily operations.

Separating operations does not sever common ownership. No published guidance has addressed the difference, and the DEA has not said how it will resolve it. Any commingled operator should be asking this question of counsel now rather than after a decision arrives.

A treaty obligation. The Single Convention requires that a government agency serve as the exclusive purchaser of cannabis production. To satisfy it, registered manufacturers establish a nominal price for their crops. The DEA purchases at that price and immediately resells at the same price plus an administrative fee.

The crop does not move. What does matter is that registered manufacturers must store crops in a facility to which the DEA maintains access until the transaction completes, and each manufacturer registration must specify the areas where cultivation is permitted. That has real consequences for how a site is designed and documented.

Manufacturers should plan for it. The Single Convention requires quota controls, and the order directs the Administrator to take the Single Convention's requirements, including any quota requirement, into account when evaluating applications. The Administrator is also authorized to require the recordkeeping and reporting necessary to comply with the treaty.

A quota framework for state licensed manufacturers has not been built. It will require separate rulemaking, and it will carry reporting obligations to the International Narcotics Control Board.

Nothing has been issued. That is not a reason to ignore it. Quota administration and controlled substance reporting are among the more demanding obligations a registrant carries, and the operators who understand them before they arrive will have a considerable advantage over the ones who meet them for the first time in a notice.